Zetomipzomib

Kezar Life Sciences secured an FDA meeting to discuss zetomipzomib for autoimmune hepatitis. The meeting will focus on designing a Phase 2b clinical study for relapsed and refractory AIH patients. Kezar provided pharmacokinetic and safety data, seeking to amend monitoring requirements and align on trial conduct. This move aims to advance zetomipzomib, a potential treatment for a serious condition with unmet needs.